About Xeris Biopharma Holdings Inc.

Xeris Biopharma was formed in 2021 through the merger of Xeris Pharmaceuticals and Strongbridge Biopharma, combining complementary portfolios and capabilities in specialty pharmaceuticals. The company has built its foundation on innovative formulation technology that enables stable, ready-to-use presentations of drugs that typically require reconstitution. Xeris's flagship product, Gvoke, revolutionized emergency treatment of severe hypoglycemia by providing the first ready-to-use, room-temperature stable glucagon. The company's expansion into endocrinology with Recorlev for Cushing's syndrome demonstrates its strategy of addressing underserved patient populations. XERS stock price reflects investor evaluation of the company's commercial execution, pipeline potential, and ability to leverage its technology platform.

Under the leadership of CEO Paul Edick, who co-founded Xeris Pharmaceuticals, the company has focused on building a sustainable specialty pharmaceutical business. The management team combines expertise in drug formulation, commercial operations, and business development, essential for competing in specialty markets. Leadership has prioritized expanding the commercial reach of existing products while advancing pipeline programs using the company's formulation technologies. Their strategic vision for becoming a leader in ready-to-use injectable medicines has guided resource allocation and partnership decisions that influence XERS stock price performance.

Xeris Biopharma generates revenue primarily through sales of Gvoke for severe hypoglycemia and Recorlev for endogenous Cushing's syndrome. The company's technology platform, XeriSol and XeriJect, enables development of ready-to-use formulations of peptides, proteins, and small molecules. Pipeline programs include ready-to-use glucagon for additional indications and other hormone therapies. The business model focuses on specialty markets where improved convenience and stability provide meaningful clinical benefits. Key growth drivers include expanding adoption of marketed products, label expansions, and leveraging the technology platform for new products or partnerships. These commercial and development activities, combined with the company's focus on endocrinology and metabolic diseases, are fundamental factors affecting XERS stock price and its potential as a growth-oriented specialty pharmaceutical investment.